Bioventus (BVS) Cash & Current Investments (2020 - 2026)

Bioventus (BVS) has reported Cash & Current Investments for 7 consecutive years, with $29.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 10.49% year-over-year to $29.5 million; the trailing twelve-month figure through Jun 2026 stood at $29.5 million (down 10.49% YoY), and the FY2025 full-year result was $51.2 million, up 23.22% from the prior year.
• Cash & Current Investments retreated to $29.5 million in Q2 2026 per BVS's latest filing, from $35.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $51.2 million in Q4 2025 and bottomed at $22.8 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $35.3 million across 5 years, with a median of $33.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments plunged 75.75% in 2022, then soared 60.56% in 2024.
• Over 5 years, Cash & Current Investments stood at $30.2 million in 2022, then climbed by 22.36% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025, then plunged by 42.51% to $29.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $29.5 million, $35.8 million, and $51.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.